NEXPLANON®

NEXPLANON consists of a single, radiopaque, rod-shaped implant, containing 68 mg etonogestrel, pre-loaded in the needle of a disposable applicator. Your healthcare professional will insert the implant just under the skin of the inner side of your upper arm.

NEXPLANON is a progestin indicated for use by women to prevent pregnancy.

NEXPLANON is a hormone-releasing birth control implant for use by women to prevent pregnancy for up to 3 years. The implant is a flexible plastic rod about the size of a matchstick that contains a progestin hormone called etonogestrel. It contains a small amount of barium sulfate (15 mg), so that the implant can be seen by X-ray, an ethylene vinyl acetate (EVA) copolymer (28% vinyl acetate, 43 mg) core, and magnesium stearate (0.1 mg). You can use a single NEXPLANON implant for up to 3 years. NEXPLANON does not contain estrogen.

• The efficacy of NEXPLANON does not depend on daily, weekly, or monthly administration.
• All healthcare professionals should receive instruction and training prior to performing insertion and/or removal of NEXPLANON.
• A single NEXPLANON implant is inserted subdermally just under the skin at the inner side of the non-dominant upper arm.
• Inserting an implant more deeply than subdermally (a deep insertion) may preclude palpation and localization, making removal difficult or impossible.
• NEXPLANON must be inserted by the expiration date stated on the packaging.
• NEXPLANON is a long-acting (up to 3 years), reversible, hormonal contraceptive method.
• Timing of insertion depends on the woman’s recent contraceptive history.

Contraindications

• Known or suspected pregnancy.
• Current or past history of thrombosis or thromboembolic disorders.
• Liver tumors, benign or malignant, or active liver disease.
• Undiagnosed abnormal genital bleeding.
• Known or suspected breast cancer, personal history of breast cancer, or other progestin-sensitive cancer, now or in the past.
• Allergic reaction to any of the components of NEXPLANON.

After-care

• If inserted as recommended, back-up contraception is not necessary.
• After starting NEXPLANON, women are likely to have a change from their normal menstrual bleeding pattern.
• Abnormal bleeding should be evaluated as needed to exclude pathologic conditions or pregnancy.
• A woman should re-start contraception immediately after removal of the implant if continued contraceptive protection is desired.